IP Library › Granted Patent US 9,764,003
Granted Patent B2
US 9,764,003 · App. 14/409,493 · Granted Sep 19, 2017

Use of long-acting GLP-1 peptides

Inventor: Christine B. Jensen (Charlottenlund, DK)
Assignee: Novo Nordisk A/S
A61K38/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,764,003
App. No.
14/409,493
Granted
Sep 19, 2017
Kind
B2
Abstract

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

Claims (6)

1. A method for reducing body weight, comprising administering semaglutide once weekly in an amount of at least 0.7 mg and up to 1.6 mg to a subject in need thereof, wherein said semaglutide is administered without another therapeutic agent.

2. The method according to claim 1 , wherein said semaglutide is administered in an amount of at least 0.8 mg per week.

3. The method according to claim 1 , wherein said semaglutide is administered by parenteral administration.

4. The method according to claim 1 , wherein said semaglutide is administered once weekly at about 0.8 mg.

5. The method according to claim 1 , wherein the subject is suffering from type 2 diabetes.

6. The method according to claim 5 , wherein said semaglutide is administered by subcutaneous injection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: JENSEN, CHRISTINE B.; RASMUSSEN, MADS F.; ZDRAVKOVIC, MILAN; KRISTENSEN, PETER
To: NOVO NORDISK A/S
Reel/Frame 034908/0221 →
Priority Claims (2)
EP 12174535 · Jul 1, 2012 · regional
EP 12186781 · Oct 1, 2012 · regional
Continuity (3)
Provisional Application 61694837 · Aug 30, 2012
Provisional Application 61708162 · Oct 1, 2012
Related Publication 20150190474A1 · Jul 9, 2015